Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oregon for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oregon only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oregon (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Natasha Tiffany (NPI 1972697167)

Field	Value
Entity Type	Individual
Organization	Natasha Tiffany
Address	2500 Ne Neff Rd
City	Bend
State	OR
ZIP	97701
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 3, 2006

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

NATASHA TIFFANY is a Hematology & Oncology Physician based in BEND, OR with an NPI enumerated on 2006-10-03 (~20 years ago). Her billing footprint is concentrated in Medicare with Total Medicare revenue: $1.7M and Total Medicaid revenue: none (no Medicaid billing on file), indicating a long-tenured, Medicare-focused practice profile.

Revenue is highly concentrated in three injectable oncology agents: J9271 accounts for 51.5% of Medicare revenue, J9144 accounts for 15.7%, and J0897 accounts for 12.6%; the precomputed top-3 share is 79.8% of this provider's total Medicare revenue. This concentration shows that a small set of high-cost drug administrations drives the majority of the practice's Medicare receipts.

The service mix (dominant J9271, J9144 and supportive agent J0897 alongside chemotherapy administration codes such as 96413) is consistent with an infusion-centered oncology practice delivering high-cost monoclonal antibodies and on-site chemotherapy. The presence of G0498 and multiple infusion add-on codes (96417, 96415, 96411) supports a model that includes in-office infusion initiation and continuation.

Competitive standing by code is mixed: J9271 ranks #375 of 1841 providers nationally (79th percentile) and is described as typical, unremarkable volume for that code; J9144 ranks #362 of 615 providers nationally (39th percentile) and is also characterized as typical, unremarkable volume; J0897 ranks #844 of 10057 providers nationally (92th percentile) but is still labeled in the data as typical, unremarkable volume. These rank/percentile positions suggest the provider is a modest-to-mid-level national participant for pembrolizumab and daratumumab and comparatively higher in reported denosumab volume relative to national peers.

There is evidence of biosimilar and supportive-care utilization: Q5108 (pegfilgrastim-jmdb) contributes 3.6% of Medicare revenue and ranks #14 of 125 providers nationally (89th percentile), indicating above-peer uptake of this biosimilar within the available peer set. Additional supportive medications such as J0885 (epoetin alfa) and J1439 (ferric carboxymaltose) appear in the top codes, consistent with management of anemia and iron deficiency in oncology patients.

Operationally, the practice bills both chemotherapy drug units (J-codes) and associated administration/E&M and infusion codes (96413, 96365/96367, 99214/99215), plus in-office labs (80053, 85025, 36415), which points to integrated on-site infusion services with ancillary diagnostics and E/M visits. Notably, 96413 (chemotherapy administration) is flagged in the data as notably above typical national volume, reinforcing that active chemotherapy delivery is a material part of the clinical operations.

Payer mix risk is concentrated: with Total Medicare revenue: $1.7M and no Medicaid activity on file, the provider is effectively single-payer (Medicare) on record. That concentration means changes in Medicare policy, drug reimbursement, or utilization for the few high-revenue J-codes could disproportionately affect the provider's billed revenue.

Several ancillary and lab services appear at high national percentiles (for example 80053 and 85025 rank in the 96th percentile in the supplied data) yet are still labeled typical, unremarkable volume; this suggests consistent, in-office support services (phlebotomy and basic panels) that accompany the infusion practice rather than unusual outlier billing patterns. These ancillary items add predictable, lower-dollar revenue streams that complement the dominant high-cost drug administrations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

59 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,400	$40	$877.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,020	$40	$266.8K
J0897	Injection, denosumab, 1 mg	11,940	$20	$214.9K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	650	$90	$60.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	550	$100	$54.7K
J1439	Injection, ferric carboxymaltose, 1 mg	35,250	$1	$35.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	390	$90	$35.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	190	$130	$23.5K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	3,030	$10	$18.2K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,350	$10	$13.5K

Showing 1–10 of 59

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 59 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oregon Distribution

Natasha Tiffany — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oregon

Full comparison — all codes billed, vs. state median

59 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	8,700	$40	$430.9K
J9144	4	10	9,180	$40	$343.4K
J0897	6	70	2,400	$20	$78.3K
J0885	2	10	12,990	$10	$74.7K
J3490	2	50	40	$640	$42.9K
Q5108	1	10	300	$90	$34.3K
J1439	2	10	19,130	$1	$20.1K
96413	5	90	150	$100	$18.2K
99214	436	6,070	80	$70	$10.3K
J9041	3	10	2,870	$1	$10.1K

Showing 1–10 of 59

Related Providers

Other providers that share a Tax Identification Number (TIN) with Natasha Tiffany, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St. Charles Health System, Inc.	OR	Family Medicine Physician	$0	$8.6M
St. Charles Health System, Inc.	OR	Critical Access Hospital	$0	$5M
St. Charles Health System, Inc.	OR	General Acute Care Hospital	$0	$4.4M
Oregon Oncology Specialists, LLP	OR	Hematology & Oncology Physician	$0	$3.5M
St. Charles Health System, Inc.	OR	Critical Access Hospital	$0	$1.4M
Charles Petrunin	OR	Hematology & Oncology Physician	$758.7K	$0
Heather Hansen-dispenza	OR	Rheumatology Physician	$726.8K	$0
Nicholas Barber	OR	Hematology & Oncology Physician	$630.9K	$0
Russell Lewis	OR	Hematology & Oncology Physician	$569.3K	$0
Steven Michel	OR	Diagnostic Radiology Physician	$541.9K	$0

Nearby Providers

Other providers in the same ZIP code as Natasha Tiffany, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ortc, LLC	OR	Substance Abuse Rehabilitation Facility	$747.3K	$16.2M
Telecare Mental Heatlh Service Of Oregon, Inc	OR	Mental Illness Community Based Residential Treatment Facility	$0	$12.8M
Bend Memorial Clinic PC	OR	Family Medicine Physician	$0	$11.7M
Pfeifer & Associates	OR	Community/Behavioral Health Agency	$0	$11.6M
Grants Pass Treatment Center	OR	Substance Abuse Rehabilitation Facility	$0	$9.5M
Deschutes County Oregon	OR	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$7.9M
Central Oregon Pediatric Associates	OR	Pediatrics Physician	$0	$7.2M
Bend Surgery Center LLC	OR	Ambulatory Surgical Clinic/Center	$4.8M	$1.7M
Adam Angeles	OR	Plastic and Reconstructive Surgery Physician	$6.5M	$0
Central Oregon Emergency Physicians LLC	OR	Emergency Medical Services (Emergency Medicine) Physician	$0	$5.2M

Natasha Tiffany — Billing Profile & Reimbursement Data

Sign up for Natasha Tiffany — Billing Profile & Reimbursement Data policy alerts

Natasha Tiffany — Billing Profile & Reimbursement Data

Sign up for Natasha Tiffany — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References